The combination of Kae and Gef (gefitinib) results in a more pronounced inhibition of glioma cell proliferation compared to either treatment alone, and Kae further enhances the inhibition of EGFR and SRC phosphorylation when used alongside Gef [219]. The gene discussed is EGFR; the disease is central nervous system cancer.